Novavax, Inc.
NVAX
$9.03
$0.556.49%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.08B | 1.25B | 682.16M | 885.19M | 987.67M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.08B | 1.25B | 682.16M | 885.19M | 987.67M |
| Cost of Revenue | 450.31M | 509.49M | 556.73M | 715.61M | 773.38M |
| Gross Profit | 628.41M | 745.47M | 125.44M | 169.59M | 214.29M |
| SG&A Expenses | 241.16M | 301.79M | 336.50M | 418.39M | 458.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 712.33M | 832.15M | 914.09M | 1.18B | 1.27B |
| Operating Income | 366.39M | 422.81M | -231.93M | -290.02M | -285.83M |
| Income Before Tax | 431.39M | 488.52M | -176.62M | -279.74M | -288.88M |
| Income Tax Expenses | 8.56M | 9.82M | 10.88M | 5.12M | 5.46M |
| Earnings from Continuing Operations | 422.82 | 478.70 | -187.50 | -284.86 | -294.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 422.82M | 478.70M | -187.50M | -284.86M | -294.33M |
| EBIT | 366.39M | 422.81M | -231.93M | -290.02M | -285.83M |
| EBITDA | 407.51M | 467.50M | -183.44M | -243.25M | -240.44M |
| EPS Basic | 2.61 | 3.05 | -1.22 | -2.16 | -2.67 |
| Normalized Basic EPS | 1.50 | 1.79 | -0.85 | -1.28 | -1.61 |
| EPS Diluted | 2.29 | 2.67 | -1.32 | -2.26 | -2.77 |
| Normalized Diluted EPS | 1.28 | 1.53 | -0.93 | -1.35 | -1.68 |
| Average Basic Shares Outstanding | 643.36M | 629.72M | 608.59M | 572.02M | 515.40M |
| Average Diluted Shares Outstanding | 675.13M | 663.77M | 626.06M | 589.50M | 532.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |